Genome-wide screening identifies Polycomb repressive complex 1.3 as an essential regulator of human naïve pluripotent cell reprogramming.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
25 03 2022
Historique:
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 7 4 2022
Statut: ppublish

Résumé

Uncovering the mechanisms that establish naïve pluripotency in humans is crucial for the future applications of pluripotent stem cells including the production of human blastoids. However, the regulatory pathways that control the establishment of naïve pluripotency by reprogramming are largely unknown. Here, we use genome-wide screening to identify essential regulators as well as major impediments of human primed to naïve pluripotent stem cell reprogramming. We discover that factors essential for cell state change do not typically undergo changes at the level of gene expression but rather are repurposed with new functions. Mechanistically, we establish that the variant Polycomb complex PRC1.3 and PRDM14 jointly repress developmental and gene regulatory factors to ensure naïve cell reprogramming. In addition, small-molecule inhibitors of reprogramming impediments improve naïve cell reprogramming beyond current methods. Collectively, this work defines the principles controlling the establishment of human naïve pluripotency and also provides new insights into mechanisms that destabilize and reconfigure cell identity during cell state transitions.

Identifiants

pubmed: 35333572
doi: 10.1126/sciadv.abk0013
pmc: PMC8956265
doi:

Substances chimiques

Polycomb Repressive Complex 1 EC 2.3.2.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabk0013

Subventions

Organisme : Medical Research Council
ID : MR/T011769/1
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : P01 GM099134
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD098387
Pays : United States

Références

Nature. 2010 Nov 11;468(7321):316-20
pubmed: 20953172
BMC Bioinformatics. 2010 Apr 01;11:165
pubmed: 20356413
Development. 2019 Dec 16;146(24):
pubmed: 31740534
Cell Rep. 2016 Jun 21;15(12):2597-607
pubmed: 27292646
Cell Stem Cell. 2017 Jan 5;20(1):18-28
pubmed: 28061351
Stem Cell Reports. 2020 Jul 14;15(1):198-213
pubmed: 32619492
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6382-E6390
pubmed: 27698112
Cell Stem Cell. 2016 Jan 7;18(1):67-72
pubmed: 26712580
Nat Commun. 2018 Jun 13;9(1):2311
pubmed: 29899353
Nat Methods. 2017 Nov;14(11):1055-1062
pubmed: 28945704
Development. 2017 Aug 1;144(15):2748-2763
pubmed: 28765214
Sci Rep. 2017 Aug 7;7(1):7384
pubmed: 28785007
Development. 2019 Apr 3;146(7):
pubmed: 30944104
Development. 2015 Sep 15;142(18):3090-9
pubmed: 26395138
Nat Commun. 2015 Jun 16;6:7329
pubmed: 26076835
Bioinformatics. 2011 Apr 1;27(7):1017-8
pubmed: 21330290
Nature. 2016 Sep 1;537(7618):57-62
pubmed: 27556940
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4484-9
pubmed: 24623855
Elife. 2020 Feb 12;9:
pubmed: 32048992
Science. 2017 Jun 9;356(6342):1081-1084
pubmed: 28596365
Mol Cell. 2019 Jun 6;74(5):1037-1052.e7
pubmed: 31029542
Mol Psychiatry. 2021 Feb;26(2):666-681
pubmed: 30953002
Hybridoma. 2001 Feb;20(1):43-6
pubmed: 11289226
Cell Stem Cell. 2021 Sep 2;28(9):1549-1565.e12
pubmed: 33915080
Science. 1998 Nov 6;282(5391):1145-7
pubmed: 9804556
Mol Cell. 2012 Feb 10;45(3):344-56
pubmed: 22325352
Nat Biotechnol. 2014 Mar;32(3):267-73
pubmed: 24535568
Database (Oxford). 2014 Feb 25;2014:bau012
pubmed: 24573882
Cell Rep. 2016 Oct 18;17(4):1193-1205
pubmed: 27760321
Stem Cell Reports. 2016 Apr 12;6(4):437-446
pubmed: 26947977
Arch Toxicol. 2018 Oct;92(10):3117-3129
pubmed: 30155720
Cell Stem Cell. 2021 Jun 3;28(6):1016-1022.e4
pubmed: 33957081
Cell. 2016 May 5;165(4):1012-26
pubmed: 27062923
Cell Stem Cell. 2017 Jan 5;20(1):87-101
pubmed: 27989770
Cell Rep. 2016 Oct 4;17(2):583-595
pubmed: 27705803
Nat Rev Mol Cell Biol. 2021 Dec;22(12):815-833
pubmed: 34400841
Nature. 2014 Jul 31;511(7511):606-10
pubmed: 25079557
Cell Stem Cell. 2016 Mar 3;18(3):323-329
pubmed: 26853856
Nat Biotechnol. 2000 Apr;18(4):399-404
pubmed: 10748519
Cell Stem Cell. 2013 Mar 7;12(3):368-82
pubmed: 23333148
Cell. 2014 Sep 11;158(6):1254-1269
pubmed: 25215486
Genome Biol. 2014;15(12):554
pubmed: 25476604
Nature. 2014 Dec 18;516(7531):349-54
pubmed: 25519132
Stem Cells. 2010 Apr;28(4):713-20
pubmed: 20201064
Mol Cell. 2019 Jun 6;74(5):1020-1036.e8
pubmed: 31029541
Nat Commun. 2020 Mar 9;11(1):1282
pubmed: 32152282
Cell Stem Cell. 2021 Jun 3;28(6):1040-1056.e6
pubmed: 33831366
Nature. 2021 Mar;591(7851):620-626
pubmed: 33731924
Nature. 2020 Oct;586(7827):101-107
pubmed: 32939092
Nature. 2015 May 21;521(7552):316-21
pubmed: 25945737
Nature. 2021 Mar;591(7851):627-632
pubmed: 33731926
Nat Biotechnol. 2008 Jul;26(7):795-7
pubmed: 18568017
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Nat Struct Mol Biol. 2011 Feb;18(2):120-7
pubmed: 21183938
Cell Stem Cell. 2014 Oct 2;15(4):410-415
pubmed: 25280217
Nat Protoc. 2016 Feb;11(2):316-26
pubmed: 26797456
Development. 2018 Feb 7;145(3):
pubmed: 29361568
Nature. 2020 Jan;577(7791):537-542
pubmed: 31830756
Cell Stem Cell. 2014 Oct 2;15(4):471-487
pubmed: 25090446
Cell Rep. 2019 Jan 22;26(4):815-824.e4
pubmed: 30673604
Trends Biochem Sci. 2017 Nov;42(11):850-861
pubmed: 28964624
J Biol Chem. 2017 Dec 29;292(52):21527-21537
pubmed: 29054931
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Development. 2016 Dec 1;143(23):4368-4380
pubmed: 27660325
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Stem Cell Reports. 2019 Jun 11;12(6):1212-1222
pubmed: 31031191
Stem Cell Reports. 2020 May 12;14(5):972-988
pubmed: 32302559
Cell Stem Cell. 2017 Jun 1;20(6):874-890.e7
pubmed: 28343983
Cell Stem Cell. 2017 Jan 5;20(1):102-111
pubmed: 27989768
Chem Sci. 2015 Jan 1;6(1):804-815
pubmed: 25642316
Cell Rep. 2020 Nov 24;33(8):108419
pubmed: 33238118
Nat Rev Mol Cell Biol. 2016 Mar;17(3):155-69
pubmed: 26860365
Science. 2007 Dec 21;318(5858):1917-20
pubmed: 18029452
Nat Commun. 2016 Jul 07;7:12144
pubmed: 27385103

Auteurs

Amanda J Collier (AJ)

Epigenetics Programme, Babraham Institute, Cambridge, UK.
Department of Biological Chemistry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.

Adam Bendall (A)

Epigenetics Programme, Babraham Institute, Cambridge, UK.

Charlene Fabian (C)

Epigenetics Programme, Babraham Institute, Cambridge, UK.

Andrew A Malcolm (AA)

Epigenetics Programme, Babraham Institute, Cambridge, UK.
Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.

Katarzyna Tilgner (K)

Stem Cell Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.

Claudia I Semprich (CI)

Epigenetics Programme, Babraham Institute, Cambridge, UK.

Katarzyna Wojdyla (K)

Epigenetics Programme, Babraham Institute, Cambridge, UK.

Paola Serena Nisi (PS)

Epigenetics Programme, Babraham Institute, Cambridge, UK.

Kamal Kishore (K)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

Valar Nila Roamio Franklin (VN)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

Bahar Mirshekar-Syahkal (B)

Stem Cell Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.

Clive D'Santos (C)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

Kathrin Plath (K)

Department of Biological Chemistry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.

Kosuke Yusa (K)

Stem Cell Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.
Stem Cell Genetics, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.

Peter J Rugg-Gunn (PJ)

Epigenetics Programme, Babraham Institute, Cambridge, UK.
Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH